Skip to main content

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Written by Customer Service on . Posted in Public Companies.

Study reports sustained IOP reduction and reduced medication burden over 24 months

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse® Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma.

“These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with early-stage glaucoma, as well as in those with moderate and advanced disease,” said Michele Lanza, MD, lead author of the study. “The findings suggest that MicroPulse TLT may have a role earlier in the glaucoma treatment continuum than has traditionally been considered.”

Published in the International Journal of Ophthalmology, the retrospective study evaluated 84 eyes of 53 patients with primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG). Led by Dr. Lanza of the Università della Campania Luigi Vanvitelli in Naples, Italy, the study used the Iridex Cyclo G6® Laser with the original MicroPulse® P3 Delivery Device. Patients with prior incisional glaucoma surgery were excluded, while those who had undergone selective laser trabeculoplasty (SLT) more than three years earlier remained eligible for inclusion.

“We are encouraged by the sustained outcomes reported in this study and the growing body of clinical evidence supporting MicroPulse TLT,” said Patrick Mercer, President and Chief Executive Officer of Iridex. “These findings further reinforce our commitment to advancing laser-based treatment options for patients with glaucoma.”

Key Findings at 24 Months

  • Mean intraocular pressure (IOP) decreased significantly from 22.32 mmHg at baseline to 14.05 mmHg, with reductions sustained throughout the two-year follow-up
  • Mean number of topical IOP-lowering medications decreased from 2.96 at baseline to 2.38
  • Treatment success rates were 86% in POAG eyes and 81% in PACG eyes
  • No complications or reductions in visual acuity were reported during follow-up

Additional findings included the discontinuation of oral acetazolamide among all patients receiving the medication before MicroPulse TLT, with none requiring reinitiation during the two-year follow-up period. Further, visual field measurements remained stable during follow-up in both the POAG and PACG groups.

About the Study

Lanza M, Fattore I, Ambrosio S, Abbate F, Boccia R, Serra L, Cangiano T, Simonelli F. Safety and efficacy of micropulse transscleral laser therapy for glaucoma: a two-year follow-up. International Journal of Ophthalmology. 2026;19(9):1731-1738. doi:10.18240/ijo.2026.09.08.

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.

For additional information, visit www.iridex.com.

Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com

Media Contact
Joan Stauffer
jstauffer@iridex.com

Iridex, the Iridex logo, MicroPulse, the MicroPulse logo, Cyclo G6, and MicroPulse P3 are registered trademarks of Iridex.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.